Covid-19 roundup: AstraZeneca launches 3rd US PhIII vaccine study with a vow to avoid 'cutting corners'
AstraZeneca has launched the final round of US testing for their closely-watched Oxford vaccine for Covid-19, taking the third spot in line just behind Moderna and the Pfizer/BioNTech team.
As they announced the move, AstraZeneca CEO Pascal Soriot stopped for a moment to highlight the principles they follow in drug and vaccine development — offering some reassurances on R&D values in the wake of the pandemonium that has erupted in the US following the plasma fiasco, as President Trump and FDA commissioner Stephen Hahn touted misleading information on plasma’s efficacy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.